Global Business Reports


Lina Jafari, Julian Issa, Margarita Todorova, Lorena Stancu

India Pharmaceuticals 2019

November 05, 2019

Known chiefly for its leadership in the generics space, India’s vast pharmaceutical market is one of the largest in the world by both volume, for which it is ranked third, and value, where it comes in at tenth. As the supplier of around 40% of generic demand in the United States and over 50% of global demand for various vaccines, the country has been aptly dubbed “the pharmacy of the world” for its critical role in supplying life saving medications to both developed and developing nations at affordable prices. While its prowess as an international pharmaceutical hub is hardly in question, India will face significant challenges in the years to come as the global industry modernizes and the renaissance in biopharmaceuticals and innovative therapies continue to alter the life sciences. As the 2020 milestone approaches, the question must be asked: how far has India come in achieving its government-led Pharma 2020 Vision to address these challenges? GBR sets out to answer this question in our latest IE publication, and following months of on-the-ground research, our field team encountered conflicting narratives across India’s three key pharmaceutical clusters: Mumbai, Hyderabad and Gujarat. 


Established in the year 2002, Surya Life Sciences is a manufacturer, exporter, and supplier of a wide assortment of bulk drug intermediates and fine API chemicals.
Aastrid Life Sciences discusses how a focus on niche molecules and a commitment to quality assurance has made the company successful.
ASE is one of the oldest pharmaceutical companies in India and re-emerged as a parent company for different subsidiaries.
Gandhi Automations is taking a leading role in introducing the benefits of automation to Indian manufacturers – including the pharma industry.


KSK Avocats, a leading law firm in Côte d’Ivoire involved in the mining industry, explains the regulations related to operating in the country.